Search for: "Schering Plough Corp"
Results 41 - 60
of 154
Sorted by Relevance
|
Sort by Date
13 Jul 2009, 9:28 pm
A tip of the old cyberhat - and not for the first time - to Alan Modlinger at Lowenstein Sandler for passing along to us the latest good news on the off-label promotion front - dismissal (with leave to replead under Twombly) in In re Schering-Plough Corp. [read post]
31 Aug 2007, 12:53 am
Schering-Plough Defends Suits Over Marketing of 'Off-Label' Drug Uses
New Jersey Law Journal
Schering-Plough Corp. faces a spate of federal court litigation over promotion of its drugs for uses not approved by the Food and Drug Administration. [read post]
15 Aug 2011, 6:01 am
Schering-Plough Corp., 2011 WL 3452398 (Cal.App. 2 Dist.) [read post]
15 Jan 2008, 12:02 am
Plaintiffs Lawyers Split $9.5M Fee in Shareholder Suit Against Schering-Plough
New Jersey Law Journal
A federal judge approved a settlement Monday in a shareholders' derivative suit against Schering-Plough Corp. with no award of damages but a $9.5 million fee to plaintiffs counsel and a company pledge to reform its governance. [read post]
20 Mar 2007, 8:19 am
**Separately**Patently-O notes the Supreme Court has requested the Solicitor General to brief issues in Tamoxifen Citrate Antitrust Litigation, a sequel to the earlier much-discussed Schering Plough case in the 11th Circuit. [read post]
24 Dec 2013, 5:49 am
Schering- Plough Corp., 320 F.3d 1339, 1345 (Fed. [read post]
23 Jan 2013, 4:16 pm
Schering-Plough Corp., 320 F.3d 1339, 1345 (Fed.Cir. 2003). [read post]
1 Dec 2011, 3:31 pm
Corp. and Schering-Plough Corp. [read post]
31 Aug 2007, 1:35 am
"
Schering-Plough Defends Suits Over Marketing of 'Off-Label' Drug Uses "Schering-Plough Corp. faces a spate of federal court litigation over promotion of its drugs for uses not approved by the Food and Drug Administration. [read post]
22 Feb 2009, 8:38 pm
Patent No. 5,807,825 ("Platelet Aggregation Inhibitors," issued September 15, 1998), licensed to Schering Corp., following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Schering-Plough's Integrilin ® (eptifibatide injection, used to treat acute coronary syndrome). [read post]
1 May 2009, 8:25 am
SEC Investigating Schering-Plough Trades: The SEC is investigating trading of Schering-Plough shares ahead of the announcement of its merger with Merck & Co., people familiar with the matter said. [read post]
15 Jun 2010, 5:28 am
In re Schering-Plough Corp. [read post]
22 Apr 2011, 10:51 am
Merck merged with Schering-Plough Corp. on Nov. 3, 2009, and, according to the complaint, had told PETA that they needed to prove ownership in Schering-Plough to be eligible. [read post]
24 Jan 2018, 11:48 am
Schering-Plough Corp., the New Jersey Supreme Court considered the legality of third-party waiver claims. [read post]
14 Dec 2017, 5:30 am
Schering-Plough Corp., December 11, 2017, Patterson, A.). [read post]
14 Jan 2008, 8:49 am
Long-Awaited Results Of ENHANCE Study Show Zocor + Zetia (= Vytorin) Does Not Improve Patient Outcomes (Posted by Tom Lamb at DrugInjuryWatch.com) A January 14, 2008 Bloomberg article, "Merck, Schering's Vytorin No Better Than Generic (Update 2)", reported the long-awaited results of a study concerning Zetia and Vytorin as well as the immediate fall-out: Merck & Co. and Schering-Plough Corp. said their combination… [read post]
16 May 2012, 1:23 pm
May 16, 2012), and In Re: Schering Plough Corp. [read post]
14 Apr 2012, 11:13 am
., Schering-Plough Corp. and Merck & Co. [read post]
23 Apr 2007, 2:25 am
Schering-Plough Sued in N.J. for Marketing Drugs for Off-Label Uses A raft of lawsuits centered in New Jersey allege Schering-Plough Corp. offered bribes, kickbacks and other incentives to doctors to get them to prescribe its hepatitis and cancer drugs for uses not approved by the Food and Drug Administration Racial-Profiling Claim Gets Priority Over State's Attenuation Argument A criminal… [read post]
24 May 2011, 2:09 pm
Court of Appeals for the Third Circuit, involves a settlement between Schering-Plough Corp., which owned a key patent (now expired) for the high blood pressure medication K-Dur 20, and generic drug makers Upsher Smith and ESI (formerly a division of Wyeth). [read post]
